Skip to main content
NCBI home page
The EMBO Journal logoLink to The EMBO Journal
. 1999 Mar 15;18(6):1660–1672. doi: 10.1093/emboj/18.6.1660

A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking.

J M Stommel 1, N D Marchenko 1, G S Jimenez 1, U M Moll 1, T J Hope 1, G M Wahl 1
PMCID: PMC1171253  PMID: 10075936

Abstract

Appropriate subcellular localization is crucial for regulating p53 function. We show that p53 export is mediated by a highly conserved leucine-rich nuclear export signal (NES) located in its tetramerization domain. Mutation of NES residues prevented p53 export and hampered tetramer formation. Although the p53-binding protein MDM2 has an NES and has been proposed to mediate p53 export, we show that the intrinsic p53 NES is both necessary and sufficient for export. This report also demonstrates that the cytoplasmic localization of p53 in neuroblastoma cells is due to its hyperactive nuclear export: p53 in these cells can be trapped in the nucleus by the export-inhibiting drug leptomycin B or by binding a p53-tetramerization domain peptide that masks the NES. We propose a model in which regulated p53 tetramerization occludes its NES, thereby ensuring nuclear retention of the DNA-binding form. We suggest that attenuation of p53 function involves the conversion of tetramers into monomers or dimers, in which the NES is exposed to the proteins which mediate their export to the cytoplasm.

Full Text

The Full Text of this article is available as a PDF (564.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aladjem M. I., Spike B. T., Rodewald L. W., Hope T. J., Klemm M., Jaenisch R., Wahl G. M. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol. 1998 Jan 29;8(3):145–155. doi: 10.1016/s0960-9822(98)70061-2. [DOI] [PubMed] [Google Scholar]
  2. Askjaer P., Jensen T. H., Nilsson J., Englmeier L., Kjems J. The specificity of the CRM1-Rev nuclear export signal interaction is mediated by RanGTP. J Biol Chem. 1998 Dec 11;273(50):33414–33422. doi: 10.1074/jbc.273.50.33414. [DOI] [PubMed] [Google Scholar]
  3. Bachelerie F., Rodriguez M. S., Dargemont C., Rousset D., Thomas D., Virelizier J. L., Arenzana-Seisdedos F. Nuclear export signal of IkappaBalpha interferes with the Rev-dependent posttranscriptional regulation of human immunodeficiency virus type I. J Cell Sci. 1997 Nov;110(Pt 22):2883–2893. doi: 10.1242/jcs.110.22.2883. [DOI] [PubMed] [Google Scholar]
  4. Bischoff J. R., Friedman P. N., Marshak D. R., Prives C., Beach D. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4766–4770. doi: 10.1073/pnas.87.12.4766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bogerd H. P., Fridell R. A., Benson R. E., Hua J., Cullen B. R. Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay. Mol Cell Biol. 1996 Aug;16(8):4207–4214. doi: 10.1128/mcb.16.8.4207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bosari S., Viale G., Roncalli M., Graziani D., Borsani G., Lee A. K., Coggi G. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol. 1995 Sep;147(3):790–798. [PMC free article] [PubMed] [Google Scholar]
  7. Cheng R., Ford B. L., O'Neal P. E., Mathews C. Z., Bradford C. S., Thongtan T., Barnes D. W., Hendricks J. D., Bailey G. S. Zebrafish (Danio rerio) p53 tumor suppressor gene: cDNA sequence and expression during embryogenesis. Mol Mar Biol Biotechnol. 1997 Jun;6(2):88–97. [PubMed] [Google Scholar]
  8. Chernov M. V., Ramana C. V., Adler V. V., Stark G. R. Stabilization and activation of p53 are regulated independently by different phosphorylation events. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2284–2289. doi: 10.1073/pnas.95.5.2284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chernova O. B., Chernov M. V., Ishizaka Y., Agarwal M. L., Stark G. R. MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification. Mol Cell Biol. 1998 Jan;18(1):536–545. doi: 10.1128/mcb.18.1.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Clore G. M., Ernst J., Clubb R., Omichinski J. G., Kennedy W. M., Sakaguchi K., Appella E., Gronenborn A. M. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat Struct Biol. 1995 Apr;2(4):321–333. doi: 10.1038/nsb0495-321. [DOI] [PubMed] [Google Scholar]
  11. Crook T., Marston N. J., Sara E. A., Vousden K. H. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell. 1994 Dec 2;79(5):817–827. doi: 10.1016/0092-8674(94)90071-x. [DOI] [PubMed] [Google Scholar]
  12. David-Pfeuty T., Chakrani F., Ory K., Nouvian-Dooghe Y. Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells. Cell Growth Differ. 1996 Sep;7(9):1211–1225. [PubMed] [Google Scholar]
  13. Fischer U., Huber J., Boelens W. C., Mattaj I. W., Lührmann R. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell. 1995 Aug 11;82(3):475–483. doi: 10.1016/0092-8674(95)90436-0. [DOI] [PubMed] [Google Scholar]
  14. Fornerod M., Ohno M., Yoshida M., Mattaj I. W. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell. 1997 Sep 19;90(6):1051–1060. doi: 10.1016/s0092-8674(00)80371-2. [DOI] [PubMed] [Google Scholar]
  15. Freedman D. A., Levine A. J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol. 1998 Dec;18(12):7288–7293. doi: 10.1128/mcb.18.12.7288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Friedman P. N., Chen X., Bargonetti J., Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3319–3323. doi: 10.1073/pnas.90.8.3319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 1993 Feb;8(2):307–318. [PubMed] [Google Scholar]
  18. Gerace L. Nuclear export signals and the fast track to the cytoplasm. Cell. 1995 Aug 11;82(3):341–344. doi: 10.1016/0092-8674(95)90420-4. [DOI] [PubMed] [Google Scholar]
  19. Görlich D., Mattaj I. W. Nucleocytoplasmic transport. Science. 1996 Mar 15;271(5255):1513–1518. doi: 10.1126/science.271.5255.1513. [DOI] [PubMed] [Google Scholar]
  20. Hainaut P., Hall A., Milner J. Analysis of p53 quaternary structure in relation to sequence-specific DNA binding. Oncogene. 1994 Jan;9(1):299–303. [PubMed] [Google Scholar]
  21. Halazonetis T. D., Kandil A. N. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 1993 Dec 15;12(13):5057–5064. doi: 10.1002/j.1460-2075.1993.tb06199.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997 May 15;387(6630):296–299. doi: 10.1038/387296a0. [DOI] [PubMed] [Google Scholar]
  23. Heyman R. A., Mangelsdorf D. J., Dyck J. A., Stein R. B., Eichele G., Evans R. M., Thaller C. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 1992 Jan 24;68(2):397–406. doi: 10.1016/0092-8674(92)90479-v. [DOI] [PubMed] [Google Scholar]
  24. Huang C. C., Pettersen E. F., Klein T. E., Ferrin T. E., Langridge R. Conic: a fast renderer for space-filling molecules with shadows. J Mol Graph. 1991 Dec;9(4):230-6, 242. doi: 10.1016/0263-7855(91)80016-s. [DOI] [PubMed] [Google Scholar]
  25. Hupp T. R., Lane D. P. Allosteric activation of latent p53 tetramers. Curr Biol. 1994 Oct 1;4(10):865–875. doi: 10.1016/s0960-9822(00)00195-0. [DOI] [PubMed] [Google Scholar]
  26. Hupp T. R., Meek D. W., Midgley C. A., Lane D. P. Regulation of the specific DNA binding function of p53. Cell. 1992 Nov 27;71(5):875–886. doi: 10.1016/0092-8674(92)90562-q. [DOI] [PubMed] [Google Scholar]
  27. Ishioka C., Shimodaira H., Englert C., Shimada A., Osada M., Jia L. Q., Suzuki T., Gamo M., Kanamaru R. Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells. Biochem Biophys Res Commun. 1997 Mar 6;232(1):54–60. doi: 10.1006/bbrc.1997.6216. [DOI] [PubMed] [Google Scholar]
  28. Jeffrey P. D., Gorina S., Pavletich N. P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 1995 Mar 10;267(5203):1498–1502. doi: 10.1126/science.7878469. [DOI] [PubMed] [Google Scholar]
  29. Jones S. N., Roe A. E., Donehower L. A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995 Nov 9;378(6553):206–208. doi: 10.1038/378206a0. [DOI] [PubMed] [Google Scholar]
  30. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J. C., Valent A., Minty A., Chalon P., Lelias J. M., Dumont X. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997 Aug 22;90(4):809–819. doi: 10.1016/s0092-8674(00)80540-1. [DOI] [PubMed] [Google Scholar]
  31. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991 Dec 1;51(23 Pt 1):6304–6311. [PubMed] [Google Scholar]
  32. Khokhlatchev A. V., Canagarajah B., Wilsbacher J., Robinson M., Atkinson M., Goldsmith E., Cobb M. H. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell. 1998 May 15;93(4):605–615. doi: 10.1016/s0092-8674(00)81189-7. [DOI] [PubMed] [Google Scholar]
  33. Kim F. J., Beeche A. A., Hunter J. J., Chin D. J., Hope T. J. Characterization of the nuclear export signal of human T-cell lymphotropic virus type 1 Rex reveals that nuclear export is mediated by position-variable hydrophobic interactions. Mol Cell Biol. 1996 Sep;16(9):5147–5155. doi: 10.1128/mcb.16.9.5147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Klotzsche O., Etzrodt D., Hohenberg H., Bohn W., Deppert W. Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament protein (vimentin) scaffold. Oncogene. 1998 Jul 2;16(26):3423–3434. doi: 10.1038/sj.onc.1202155. [DOI] [PubMed] [Google Scholar]
  35. Ko L. J., Prives C. p53: puzzle and paradigm. Genes Dev. 1996 May 1;10(9):1054–1072. doi: 10.1101/gad.10.9.1054. [DOI] [PubMed] [Google Scholar]
  36. Komarova E. A., Zelnick C. R., Chin D., Zeremski M., Gleiberman A. S., Bacus S. S., Gudkov A. V. Intracellular localization of p53 tumor suppressor protein in gamma-irradiated cells is cell cycle regulated and determined by the nucleus. Cancer Res. 1997 Dec 1;57(23):5217–5220. [PubMed] [Google Scholar]
  37. Kubbutat M. H., Jones S. N., Vousden K. H. Regulation of p53 stability by Mdm2. Nature. 1997 May 15;387(6630):299–303. doi: 10.1038/387299a0. [DOI] [PubMed] [Google Scholar]
  38. Kussie P. H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A. J., Pavletich N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996 Nov 8;274(5289):948–953. doi: 10.1126/science.274.5289.948. [DOI] [PubMed] [Google Scholar]
  39. Lee W., Harvey T. S., Yin Y., Yau P., Litchfield D., Arrowsmith C. H. Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol. 1994 Dec;1(12):877–890. doi: 10.1038/nsb1294-877. [DOI] [PubMed] [Google Scholar]
  40. Levine A. J. p53, the cellular gatekeeper for growth and division. Cell. 1997 Feb 7;88(3):323–331. doi: 10.1016/s0092-8674(00)81871-1. [DOI] [PubMed] [Google Scholar]
  41. Liang S. H., Hong D., Clarke M. F. Cooperation of a single lysine mutation and a C-terminal domain in the cytoplasmic sequestration of the p53 protein. J Biol Chem. 1998 Jul 31;273(31):19817–19821. doi: 10.1074/jbc.273.31.19817. [DOI] [PubMed] [Google Scholar]
  42. Lin J., Chen J., Elenbaas B., Levine A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 1994 May 15;8(10):1235–1246. doi: 10.1101/gad.8.10.1235. [DOI] [PubMed] [Google Scholar]
  43. Linke S. P., Clarkin K. C., Di Leonardo A., Tsou A., Wahl G. M. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 1996 Apr 15;10(8):934–947. doi: 10.1101/gad.10.8.934. [DOI] [PubMed] [Google Scholar]
  44. Lomax M. E., Barnes D. M., Hupp T. R., Picksley S. M., Camplejohn R. S. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene. 1998 Aug 6;17(5):643–649. doi: 10.1038/sj.onc.1201974. [DOI] [PubMed] [Google Scholar]
  45. Lou M. A., Tseng S. L., Chang S. F., Yue C. T., Chang B. L., Chou C. H., Yang S. L., Teh B. H., Wu C. W., Shen C. Y. Novel patterns of p53 abnormality in breast cancer from Taiwan: experience from a low-incidence area. Br J Cancer. 1997;75(5):746–751. doi: 10.1038/bjc.1997.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Lu H., Taya Y., Ikeda M., Levine A. J. Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6399–6402. doi: 10.1073/pnas.95.11.6399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Martinez J. D., Pennington M. E., Craven M. T., Warters R. L., Cress A. E. Free radicals generated by ionizing radiation signal nuclear translocation of p53. Cell Growth Differ. 1997 Sep;8(9):941–949. [PubMed] [Google Scholar]
  48. Mateu M. G., Fersht A. R. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. EMBO J. 1998 May 15;17(10):2748–2758. doi: 10.1093/emboj/17.10.2748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. McLure K. G., Lee P. W. How p53 binds DNA as a tetramer. EMBO J. 1998 Jun 15;17(12):3342–3350. doi: 10.1093/emboj/17.12.3342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Middeler G., Zerf K., Jenovai S., Thulig A., Tschödrich-Rotter M., Kubitscheck U., Peters R. The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited. Oncogene. 1997 Mar 27;14(12):1407–1417. doi: 10.1038/sj.onc.1200949. [DOI] [PubMed] [Google Scholar]
  51. Moll U. M., LaQuaglia M., Bénard J., Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4407–4411. doi: 10.1073/pnas.92.10.4407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Moll U. M., Ostermeyer A. G., Haladay R., Winkfield B., Frazier M., Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol. 1996 Mar;16(3):1126–1137. doi: 10.1128/mcb.16.3.1126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Moll U. M., Riou G., Levine A. J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7262–7266. doi: 10.1073/pnas.89.15.7262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Momand J., Jung D., Wilczynski S., Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998 Aug 1;26(15):3453–3459. doi: 10.1093/nar/26.15.3453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Moser F. G., Dorman B. P., Ruddle F. H. Mouse-human heterokaryon analysis with a 33258 Hoechst-Giemsa technique. J Cell Biol. 1975 Sep;66(3):676–680. doi: 10.1083/jcb.66.3.676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Norris P. S., Haas M. A fluorescent p53GFP fusion protein facilitates its detection in mammalian cells while retaining the properties of wild-type p53. Oncogene. 1997 Oct;15(18):2241–2247. doi: 10.1038/sj.onc.1201406. [DOI] [PubMed] [Google Scholar]
  57. Oliner J. D., Pietenpol J. A., Thiagalingam S., Gyuris J., Kinzler K. W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993 Apr 29;362(6423):857–860. doi: 10.1038/362857a0. [DOI] [PubMed] [Google Scholar]
  58. Osada M., Ohba M., Kawahara C., Ishioka C., Kanamaru R., Katoh I., Ikawa Y., Nimura Y., Nakagawara A., Obinata M. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med. 1998 Jul;4(7):839–843. doi: 10.1038/nm0798-839. [DOI] [PubMed] [Google Scholar]
  59. Ossareh-Nazari B., Bachelerie F., Dargemont C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science. 1997 Oct 3;278(5335):141–144. doi: 10.1126/science.278.5335.141. [DOI] [PubMed] [Google Scholar]
  60. Ostermeyer A. G., Runko E., Winkfield B., Ahn B., Moll U. M. Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15190–15194. doi: 10.1073/pnas.93.26.15190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Paulson T. G., Almasan A., Brody L. L., Wahl G. M. Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage. Mol Cell Biol. 1998 May;18(5):3089–3100. doi: 10.1128/mcb.18.5.3089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Pfeifer G. P., Holmquist G. P. Mutagenesis in the P53 gene. Biochim Biophys Acta. 1997 Aug 8;1333(1):M1–M8. doi: 10.1016/s0304-419x(97)00004-8. [DOI] [PubMed] [Google Scholar]
  63. Pietenpol J. A., Tokino T., Thiagalingam S., el-Deiry W. S., Kinzler K. W., Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):1998–2002. doi: 10.1073/pnas.91.6.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Price B. D., Hughes-Davies L., Park S. J. Cdk2 kinase phosphorylates serine 315 of human p53 in vitro. Oncogene. 1995 Jul 6;11(1):73–80. [PubMed] [Google Scholar]
  65. Roth J., Dobbelstein M., Freedman D. A., Shenk T., Levine A. J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 1998 Jan 15;17(2):554–564. doi: 10.1093/emboj/17.2.554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Sakaguchi K., Sakamoto H., Lewis M. S., Anderson C. W., Erickson J. W., Appella E., Xie D. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry. 1997 Aug 19;36(33):10117–10124. doi: 10.1021/bi970759w. [DOI] [PubMed] [Google Scholar]
  67. Schlamp C. L., Poulsen G. L., Nork T. M., Nickells R. W. Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells. J Natl Cancer Inst. 1997 Oct 15;89(20):1530–1536. doi: 10.1093/jnci/89.20.1530. [DOI] [PubMed] [Google Scholar]
  68. Shaulsky G., Ben-Ze'ev A., Rotter V. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene. 1990 Nov;5(11):1707–1711. [PubMed] [Google Scholar]
  69. Shaulsky G., Goldfinger N., Ben-Ze'ev A., Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol. 1990 Dec;10(12):6565–6577. doi: 10.1128/mcb.10.12.6565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Sherr C. J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 1998 Oct 1;12(19):2984–2991. doi: 10.1101/gad.12.19.2984. [DOI] [PubMed] [Google Scholar]
  71. Shieh S. Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997 Oct 31;91(3):325–334. doi: 10.1016/s0092-8674(00)80416-x. [DOI] [PubMed] [Google Scholar]
  72. Soussi T., May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J Mol Biol. 1996 Aug 2;260(5):623–637. doi: 10.1006/jmbi.1996.0425. [DOI] [PubMed] [Google Scholar]
  73. Stenmark-Askmalm M., Stål O., Sullivan S., Ferraud L., Sun X. F., Carstensen J., Nordenskjöld B. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer. 1994;30A(2):175–180. doi: 10.1016/0959-8049(94)90082-5. [DOI] [PubMed] [Google Scholar]
  74. Sun X. F., Carstensen J. M., Zhang H., Stål O., Wingren S., Hatschek T., Nordenskjöld B. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet. 1992 Dec 5;340(8832):1369–1373. doi: 10.1016/0140-6736(92)92558-w. [DOI] [PubMed] [Google Scholar]
  75. Tarunina M., Grimaldi M., Ruaro E., Pavlenko M., Schneider C., Jenkins J. R. Selective loss of endogenous p21waf1/cip1 induction underlies the G1 checkpoint defect of monomeric p53 proteins. Oncogene. 1996 Aug 1;13(3):589–598. [PubMed] [Google Scholar]
  76. Ueda H., Ullrich S. J., Gangemi J. D., Kappel C. A., Ngo L., Feitelson M. A., Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet. 1995 Jan;9(1):41–47. doi: 10.1038/ng0195-41. [DOI] [PubMed] [Google Scholar]
  77. Ullman K. S., Powers M. A., Forbes D. J. Nuclear export receptors: from importin to exportin. Cell. 1997 Sep 19;90(6):967–970. doi: 10.1016/s0092-8674(00)80361-x. [DOI] [PubMed] [Google Scholar]
  78. Varley J. M., McGown G., Thorncroft M., Cochrane S., Morrison P., Woll P., Kelsey A. M., Mitchell E. L., Boyle J., Birch J. M. A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome. Oncogene. 1996 Jun 6;12(11):2437–2442. [PubMed] [Google Scholar]
  79. Wahl G. M., Linke S. P., Paulson T. G., Huang L. C. Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv. 1997;29:183–219. [PubMed] [Google Scholar]
  80. Wang P., Reed M., Wang Y., Mayr G., Stenger J. E., Anderson M. E., Schwedes J. F., Tegtmeyer P. p53 domains: structure, oligomerization, and transformation. Mol Cell Biol. 1994 Aug;14(8):5182–5191. doi: 10.1128/mcb.14.8.5182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Waterman J. L., Shenk J. L., Halazonetis T. D. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J. 1995 Feb 1;14(3):512–519. doi: 10.1002/j.1460-2075.1995.tb07027.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Wen W., Meinkoth J. L., Tsien R. Y., Taylor S. S. Identification of a signal for rapid export of proteins from the nucleus. Cell. 1995 Aug 11;82(3):463–473. doi: 10.1016/0092-8674(95)90435-2. [DOI] [PubMed] [Google Scholar]
  83. Wolff B., Sanglier J. J., Wang Y. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol. 1997 Feb;4(2):139–147. doi: 10.1016/s1074-5521(97)90257-x. [DOI] [PubMed] [Google Scholar]
  84. Wu X., Bayle J. H., Olson D., Levine A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993 Jul;7(7A):1126–1132. doi: 10.1101/gad.7.7a.1126. [DOI] [PubMed] [Google Scholar]
  85. Yang J., Bardes E. S., Moore J. D., Brennan J., Powers M. A., Kornbluth S. Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1. Genes Dev. 1998 Jul 15;12(14):2131–2143. doi: 10.1101/gad.12.14.2131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Zhu J., Shibasaki F., Price R., Guillemot J. C., Yano T., Dötsch V., Wagner G., Ferrara P., McKeon F. Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1. Cell. 1998 May 29;93(5):851–861. doi: 10.1016/s0092-8674(00)81445-2. [DOI] [PubMed] [Google Scholar]

Articles from The EMBO Journal are provided here courtesy of Nature Publishing Group

RESOURCES